Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway

References

• Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Nemmar A, Ali BH. 2019. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice. Naunyn-Schmiedeberg’s Arch Pharmacol. 392:45–53. doi: 10.1007/s00210-018-1564-7.
   Google Scholar
• Abdel-Wahab AF, Bamagous GA, Al-Harizy RM, ElSawy NA, Shahzad N, Ibrahim IA, Ghamdi SSA. 2018. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy. Biomed Pharmacother. 103:59–66. doi: 10.1016/j.biopha.2018.03.176.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Sattar MZ, Rathore HA, Khan SA, Lazhari MA, Hashmi F, Abdullah NA, Johns EJ. 2015. Impact of isoprenaline and caffeine on development of left ventricular hypertrophy and renal hemodynamic in wistar kyoto rats. Acta Pol Pharm. 72:1015–1026.
   PubMed Web of Science ®Google Scholar
• Ahmed R, Tanvir EM, Hossen MS, Afroz R, Ahmmed I, Rumpa NE, Paul S, Gan SH, Sulaiman SA, Khalil MI. 2017. Antioxidant properties and cardioprotective mechanism of Malaysian propolis in rats. Evid Based Comple Alt Med eCAM. 2017:5370545. doi: 10.1155/2017/5370545.
   PubMed Web of Science ®Google Scholar
• Aragón-Herrera A, Feijóo-Bandín S, Otero Santiago M, Barral L, Campos-Toimil M, Gil-Longo J, Costa Pereira TM, García-Caballero T, Rodríguez-Segade S, Rodríguez J, Tarazón E, Roselló-Lletí E, Portolés M, Gualillo O, González-Juanatey JR, Lago F. 2019. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem Pharmacol. 170:113677. doi: 10.1016/j.bcp.2019.113677.
   PubMed Web of Science ®Google Scholar
• Araujo JA, Zhang M, Yin F. 2012. Heme oxygenase-1, oxidation, inflammation, and atherosclerosis. Front Pharmacol. 3:119–123. doi: 10.3389/fphar.2012.00119.
   PubMed Web of Science ®Google Scholar
• Behnammanesh G, Durante GL, Khanna YP, Peyton KJ, Durante W. 2020. Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1. Redox Biol. 32:101527. doi: 10.1016/j.redox.2020.101527.
   PubMed Web of Science ®Google Scholar
• Carbone S, Dixon DL. 2019. The CANVAS program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 18:64–70. doi: 10.1186/s12933-019-0869-2.
   PubMed Web of Science ®Google Scholar
• Davel AP, Brum PC, Rossoni LV, Torrens C. 2014. Isoproterenol induces vascular oxidative stress and endothelial dysfunction via a giα-coupled β2-adrenoceptor signaling pathway. PloS One. 9:e91877. doi: 10.1371/journal.pone.0091877.
   PubMed Web of Science ®Google Scholar
• Davel AP, Fukuda LE, De Sá LL, Munhoz CD, Scavone C, Sanz-Rosa D, Cachofeiro V, Lahera V, Rossoni LV. 2008. Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol Heart Circ Physiol. 295:H211–H219. doi: 10.1152/ajpheart.00581.2007.
   PubMed Web of Science ®Google Scholar
• de Ponte MC, Casare FAM, Costa-Pessoa JM, Cardoso VG, Malnic G, Mello-Aires M, Volpini RA, Thieme K, Oliveira-Souza M. 2017. The role of β-adrenergic overstimulation in the early stages of renal injury. Kidney Blood Press Res. 42:1277–1289. doi: 10.1159/000485931.
   PubMed Web of Science ®Google Scholar
• Devika PT, Stanely Mainzen Prince P. 2008. Protective effect of (-)-epigallocatechin-gallate (EGCG) on lipid peroxide metabolism in isoproterenol induced myocardial infarction in male wistar rats: a histopathological study. Biomed Pharmacother. 62:701–708. doi: 10.1016/j.biopha.2007.10.011.
   PubMed Web of Science ®Google Scholar
• Drexler H, Kästner S, Strobel A, Studer R, Brodde OE, Hasenfuss G. 1998. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol. 32:955–963. doi: 10.1016/s0735-1097(98)00336-2.
   PubMed Web of Science ®Google Scholar
• El-Daly M, Pulakazhi Venu VK, Saifeddine M, Mihara K, Kang S, Fedak PWM, Alston LA, Hirota SA, Ding H, Triggle CR, Hollenberg MD. 2018. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vascul Pharmacol. 109:56–71. doi: 10.1016/j.vph.2018.06.006.
   PubMed Web of Science ®Google Scholar
• Feng Q, Lu X, Jones DL, Shen J, Arnold JM. 2001. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation. 104:700–704. doi: 10.1161/hc3201.092284.
   PubMed Web of Science ®Google Scholar
• Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. 2000. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 101:660–667. doi: 10.1161/01.cir.101.6.660.
   PubMed Web of Science ®Google Scholar
• Ghartavol MM, Gholizadeh-Ghaleh Aziz S, Babaei G, Hossein Farjah G, Hassan Khadem Ansari M. 2019. The protective impact of betaine on the tissue structure and renal function in isoproterenol-induced myocardial infarction in rat. Mol Genet Genomic Med. 7:e00579. doi: 10.1002/mgg3.579.
   PubMed Web of Science ®Google Scholar
• Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, Choi SH, Jang HC, Lee HS, Park KS, Kim YB, Lim S. 2017. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/-mice fed a western diet. Diabetologia. 60:364–376. doi: 10.1007/s00125-016-4158-2.
   PubMed Web of Science ®Google Scholar
• Haywood G, Tsao P, von der Leyen H, Mann M, Keeling P, Trindade P, Lewis N, Byrne C, Rickenbacher P, Bishopric N, Cooke J, McKenna W, Fowler M. 1996. Expression of inducible nitric oxide synthase in human heart failure. Circulation. 93:1087–1094. doi: 10.1161/01.cir.93.6.1087.
   PubMed Web of Science ®Google Scholar
• Januzzi J, Butler J, Jarolim P, Sattar N, Vijapurkar U, Desai M, Davies M. 2017. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 70:704–712. doi: 10.1016/j.jacc.2017.06.016.
   PubMed Web of Science ®Google Scholar
• Jollow D, Mitchell J, Zampaglione N, Gillette J. 1974. Bromobenzene-induced liver necrosis. Protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic metabolite. Pharmacology. 11:151–169. doi: 10.1159/000136485.
   PubMed Web of Science ®Google Scholar
• Lahnwong S, Chattipakorn S, Chattipakorn N. 2018. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol. 17:101–110. doi: 10.1186/s12933-018-0745-5.
   PubMed Web of Science ®Google Scholar
• Lan N, Fegan P, Yeap B, Dwivedi G. 2019. The effects of sodium-glucose co-transporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 6:927–935. doi: 10.1002/ehf2.12505.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee S, Lee J, Kim J, Lee O, Kim C, Kim D, Lee Y, Oh J, Park S, Jeon O, Hong S, Ahn C, Kim B, Ko Y, Choi D, Hong M, Jang Y. 2020. Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model. Korean Circ J. 50:443–457. doi: 10.4070/kcj.2019.0296.
   PubMed Web of Science ®Google Scholar
• Lefer AM. 1995. Attenuation of myocardial ischemia-reperfusion injury with nitric oxide replacement therapy. Ann Thorac Surg. 60:847–851. doi: 10.1016/0003-4975(95)00423-I.
   PubMed Web of Science ®Google Scholar
• Leng W, Ouyang X, Lei X, Wu M, Chen L, Wu Q, Deng W, Liang Z. 2016. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE-/- mice. Mediat Inflamm. 2016:6305735. doi: 10.1155/2016/6305735.
   PubMed Web of Science ®Google Scholar
• Lim V, Bell R, Arjun S, Kolatsi-Joannou M, Long D, Yellon D. 2019. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. J Am Coll Cardiol. 4:15–26. doi: 10.1016/j.jacbts.2018.10.002.
   Google Scholar
• Liu RM, Desai L. 2015. Reciprocal regulation of TGF-β and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 6:565–577. doi: 10.1016/j.redox.2015.09.009.
   PubMed Web of Science ®Google Scholar
• Liu R, Zhang H, Yang J, Wang J, Liu J, Li C. 2018. Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. Eur Rev Med Pharmacol Sci. 22:7500–7508. doi: 10.26355/eurrev_201811_16291.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L. 2019. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 18:15–23. doi: 10.1186/s12933-019-0816-2.
   PubMed Web of Science ®Google Scholar
• Maliha G, Townsend R. 2015. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 9:48–53. doi: 10.1016/j.jash.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Mancini S, Boyd D, Katwan OJ, Strembitska A, Almabrouk TA, Kennedy S, Palmer TM, Salt I. 2018. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 8:5276–5281. doi: 10.1038/s41598-018-23420-4.
   PubMed Web of Science ®Google Scholar
• Mansuy P, Mougenot N, Ramirez-Gil J, Bonnefont-Rousselot D, Raillecove F, Komajda M, Lechat P. 2000. Effects of prolonged propranolol treatment on left ventricular remodeling and oxidative stress after myocardial infarction in rats. J Cardiovasc Pharmacol. 35:806–813. doi: 10.1097/00005344-200005000-00019.
   PubMed Web of Science ®Google Scholar
• Martina J, Simmons C, Jukic D. 2011. High-definition hematoxylin and eosin staining in a transition to digital pathology. J Pathol Inform. 2:45–52. doi: 10.4103/2153-3539.86284.
   PubMedGoogle Scholar
• Matsutani D, Sakamoto M, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K. 2018. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 17:73–81. doi: 10.1186/s12933-018-0717-9.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Ahmed L, Attia W, Khattab M. 2015. Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats. Biochem Pharmacol. 98:403–411. doi: 10.1016/j.bcp.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Moniri N, Daaka Y. 2007. Agonist-stimulated reactive oxygen species formation regulates beta 2-adrenergic receptor signal transduction. Biochem Pharmacol. 74:64–73. doi: 10.1016/j.bcp.2007.03.016.
   PubMed Web of Science ®Google Scholar
• Morisco C, Zebrowski D, Vatner D, Vatner S, Sadoshima J. 2001. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. J Mol Cell Cardiol. 33:561–573. doi: 10.1006/jmcc.2000.1332.
   PubMed Web of Science ®Google Scholar
• Nasiri-Ansari Ν, Dimitriadis G, Agrogiannis G, Perrea D, Kostakis I, Kaltsas G, Papavassiliou A, Randeva H, Kassi E. 2018. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 17:106–108. doi: 10.1186/s12933-018-0749-1.
   PubMed Web of Science ®Google Scholar
• Neal M, Perkovic V, Matthews D. 2017. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 377:2099–2102. doi: 10.1056/NEJMoa1611925.
   PubMed Web of Science ®Google Scholar
• Nishinarita R, Niwano S, Niwano H, Nakamura H, Saito D, Sato T, Matsuura G, Arakawa Y, Kobayashi S, Shirakawa Y, Horiguchi A, Ishizue N, Igarashi T, Yoshizawa T, Oikawa J, Hara Y, Katsumura T, Kishihara J, Satoh A, Fukaya H, Sakagami H, Ako J. 2021. Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model. J Am Heart Assoc. 10:e017483. doi: 10.1161/JAHA.119.017483.
   PubMed Web of Science ®Google Scholar
• Oliva R, Bakris GL. 2014. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 8:330–339. doi: 10.1016/j.jash.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Townsend R, Davies M, Vijapurkar U, Ren J. 2017. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 16:29–32. doi: 10.1186/s12933-017-0511-0.
   PubMed Web of Science ®Google Scholar
• Rådholm K, Figtree G, Perkovic V, Solomon S, Mahaffey K, de Zeeuw D, Fulcher G, Barrett T, Shaw W, Desai M, Matthews D, Neal B. 2018. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 138:458–468. doi: 10.1161/CIRCULATIONAHA.118.034222.
   PubMed Web of Science ®Google Scholar
• Rahman MM, Alam MN, Ulla A, Sumi FA, Subhan N, Khan T, Sikder B, Hossain H, Reza HM, Alam MA. 2017. Cardamom powder supplementation prevents obesity, improves glucose intolerance, inflammation and oxidative stress in liver of high carbohydrate high fat diet induced obese rats. Lipids Health Dis. 16:151–156. doi: 10.1186/s12944-017-0539-x.
   Web of Science ®Google Scholar
• Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. 2015. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann NY Acad Sci. 1358:28–43. doi: 10.1111/nyas.12852.
   PubMed Web of Science ®Google Scholar
• Safhi MM, Anwer T, Khan G, Siddiqui R, Moni Sivakumar S, Alam MF. 2018. The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats. Korean J Physiol Pharmacol. 22:493–501. doi: 10.4196/kjpp.2018.22.5.493.
   PubMed Web of Science ®Google Scholar
• Sayour AA, Korkmaz-Icöz S, Loganathan S, Ruppert M, Sayour VN, Oláh A, Benke K, Brune M, Benkő R, Horváth EM, Karck M, Merkely B, Radovits T, Szabó G. 2019. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med. 17:127–132. doi: 10.1186/s12967-019-1881-8.
   PubMed Web of Science ®Google Scholar
• Steven S, Oelze M, Hanf A, Kröller-Schön S, Kashani F, Roohani S, Welschof P, Kopp M, Gödtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Münzel T, Daiber A. 2017. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13:370–385. doi: 10.1016/j.redox.2017.06.009.
   PubMed Web of Science ®Google Scholar
• Stocks J, Dormandy TL. 1971. The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Haematol. 20:95–111. doi: 10.1111/j.1365-2141.1971.tb00790.x.
   PubMed Web of Science ®Google Scholar
• Sumi FA, Sikder B, Rahman MM, Lubna SR, Ulla A, Hossain MH, Jahan IA, Alam MA, Subhan N. 2019. Phenolic content analysis of aloe vera gel and evaluation of the effect of aloe gel supplementation on oxidative stress and fibrosis in isoprenaline-administered cardiac damage in rats. Prevent Nutr Food Sci. 24:254–264. doi: 10.3746/pnf.2019.24.3.254.
   PubMedGoogle Scholar
• Tracey WR, Tse J, Carter G. 1995. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther. 272:1011–1015.
   PubMed Web of Science ®Google Scholar
• Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. 2017. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. Hypertension. 70:103–110. doi: 10.1161/HYPERTENSIONAHA.117.09259.
   PubMed Web of Science ®Google Scholar
• Ulla A, Mohamed MK, Sikder B, Rahman AT, Sumi FA, Hossain M, Reza HM, Rahman GMS, Alam MA. 2017. Coenzyme Q10 prevents oxidative stress and fibrosis in isoprenaline induced cardiac remodeling in aged rats. BMC Pharmacol Toxicol. 18:29–33. doi: 10.1186/s40360-017-0136-7.
   PubMed Web of Science ®Google Scholar
• Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. 1996. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Internat. 49:1304–1313. doi: 10.1038/ki.1996.186.
   PubMed Web of Science ®Google Scholar
• Xu C, Wang W, Zhong J, Le F, Xu N, Zhang Y, Xie W. 2018. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol. 152:45–59. doi: 10.1016/j.bcp.2018.03.013.
   PubMed Web of Science ®Google Scholar